Browse > Article
http://dx.doi.org/10.17480/psk.2015.59.3.127

Evaluation for Effectiveness and Tolerance Duration of Initial Medication on Untreated Early Parkinson's Disease  

Cheon, Young Ju (College of Pharmacy, The Catholic University of Korea)
Park, Yong Sung (Department of Radiology, Kyunghee University Hospital at Gang-dong)
Kim, Jung Tae (Department of Pharmacy, Kyunghee University Hospital at Gang-dong)
Lim, Sung Cil (College of Pharmacy, The Catholic University of Korea)
Publication Information
YAKHAK HOEJI / v.59, no.3, 2015 , pp. 127-134 More about this Journal
Abstract
The aim of this study was to investigate the correlation among age, symptoms and initial medication (IM), and the tolerance duration of IM in Korean people with Parkinson's disease (PD). We studied 60 patients with untreated early PD who were initially diagnosed in our hospital between Jun 2006 and Sep 2014. We collected data on sex, age at diagnosis, symptom duration until diagnosis, main motor symptoms, frequency and duration of IM through electronic medical records. We divided patients into groups depending on the number of drugs (MONO/COMBI) and whether to contain dopaminergic property (DOPA/NDOPA). We analyzed the correlation between age and symptoms in each two groups and calculated the mean tolerance duration of IM in each of the groups. The mean symptom duration until diagnosis was 12.2 months. The most frequent drug was levodopa formulations (80%) compared to dopamine agonists (58.3%). The number of patients in the COMBI group (63.3%) was more than that in the MONO group (36.7%). Half of the patients in the COMBI group were taking LDF+DA (50%). Except for tremor, no other symptom showed a significant correlation between with IM. The mean tolerance duration of IM was within 200 days. The mean duration for COMBI group (342.7 days) was longer than that for MONO group (209.8 days). Among regimens, the mean tolerance duration of DOPA group (293.3 days) was longer than for NDOPA group (251.4 days). There was no difference in survival curves between any of the two groups. We found that patients experienced symptoms for over a year in Korea. This indicates that diagnosis time is faster than reported in other previous studies. The longest tolerance duration among IM was for dopaminergic combination therapy. More research is needed to design the most appropriate treatment for PD in Korean patients.
Keywords
Parkinson's disease; levodopa; initial medication; tolerance duration; levodopa; dopamine agonists;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Siuda, J., Jasinska-Myga, B., Boczarska-Jedynak, M., Opala, G., Fiesel, F. C., Moussaud-Lamodière, E. L., Scarffe, L. A., Dawson, V. L., Ross, O. A., Springer, W., Dawson, T. M. and Wszolek, Z. K. : Early-onset Parkinson's disease due to PINK1 p.Q456X mutation - Clinical and functional study. Parkinsonism Relat. Disord. 20, 1274 (2014).   DOI
2 한국임상약학회 : 약물치료학 요약집 2014, 1st ed., 도서출판 신일북스. 서울 p. 402 (2014).
3 Cheong, H. K., Lee, C. S., Kim, Y. H., Sung, J. H., Yi, S. E., Kim, J. W., Park, J. S., Kim, E. H., Kim, J. H., Jang, M. S. and Shim, M. Y. : Nationwide survey on the prevalence of Parkinson's disease in Korea. Korea Centers for Disease Control and Prevention (2007).
4 Homepage of Korea Centers for Disease Control and Prevention. URL=http://www.cdc.go.kr/CDC/cms/content/37/16537_view.html.
5 Parkinson study group : Pramipexole vs. levodopa as initial treatment for Parkinson disease, a randomized controlled study. JAMA 284, 1931 (2000).   DOI
6 Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J. and Lang, A. E. : Practice parameter: initiation of treatment for Parkinson's disease: An evidence-based review. Neurology 58, 11 (2002).   DOI
7 Tarsy, D. :Initial treatment of Parkinson's disease. Curr. Treat. Options Neurol. 8, 224 (2006).   DOI
8 Connolly, B. S. and Lang, A. E. : Pharmacological treatment of Parkinson disease - A Review. JAMA 311, 1670 (2014).   DOI
9 Tarsy, D., Hurtig, H. I. and Dashe, J. F. : Pharmacologic treatment of Parkinson disease. Uptodate, the last updated Jul (2014) URL=http://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease#H2.
10 Szewczyk-Krolikowsk, K., Tomlinson, P., Nithi, K., Wade-Martins, R., Talbot, K., Ben-Shlomo, Y. and Hu, M. T. : The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsononism Relat. Disord. 20, 99 (2014).   DOI
11 Fahn, S. : Is levodopa toxic? Neurology 47, S184 (1996).   DOI
12 NICE (National Institute for health and Care Excellence guideline) : Parkinson's disease, NICE guidelines [CG35]. published date : June 2006, Review decision date : July 2011, URL=http://www.nice.org.uk/guidance/cg035.
13 Pahwa, R. and Lyons, K. E. : Early diagnosis of Parkinson's disease: Recommendations from diagnostic clinical guidelines. Am. J. Manag. Care 16, S94 (2010).
14 Hauser, R. A. : Early pharmacologic treatment in Parkinson's disease. Am. J. Mang. Care 16, S100 (2010).
15 The Parkinson Study Group : Levodopa and the progression of Parkinson's disease. N. Eng. J. Med. 351, 2498 (2004).   DOI
16 EFNS/MDS-ES (European Federation of Neurological Societies/Movement disorder Society-European Section) guidelines : Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur. J. Neurol. 20, 5 (2013).   DOI
17 Nutt, J. G. and Wooten, G. F. : Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353, 1021 (2005).   DOI
18 Chu, M. K., Kim, W. C., Choi, J. M., Hong, J. H., Kang, S. Y., Ma, H. I. and Kim, Y. J. : Analysis of dosage mutation in PARK2 among Korean patients with early-onset or familial Parkinson's disease. J. Clin. Neurol. 10, 244 (2014).   DOI
19 Fujio, H., Inokuchi, G., Fukuda, Y., Hasegawa, S., Ootsuki, N. and Nibu, K. : A case report of Parkinson's disease presenting with olfactory disturbance as a primary symptom in the early stage. Nihon Jibiinkoka GakkaiKaiho 117, 932 (2014).   DOI